IL128107A0 - Pharmaceutical compositions containing a pkc inhibitor - Google Patents

Pharmaceutical compositions containing a pkc inhibitor

Info

Publication number
IL128107A0
IL128107A0 IL12810797A IL12810797A IL128107A0 IL 128107 A0 IL128107 A0 IL 128107A0 IL 12810797 A IL12810797 A IL 12810797A IL 12810797 A IL12810797 A IL 12810797A IL 128107 A0 IL128107 A0 IL 128107A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
pkc inhibitor
pkc
inhibitor
Prior art date
Application number
IL12810797A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL128107A0 publication Critical patent/IL128107A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12810797A 1996-08-30 1997-08-28 Pharmaceutical compositions containing a pkc inhibitor IL128107A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2487396P 1996-08-30 1996-08-30
US08/917,033 US6107327A (en) 1996-08-30 1997-08-26 Therapeutic treatment for HIV infection
PCT/US1997/015525 WO1998008509A1 (en) 1996-08-30 1997-08-28 Use of pkc inhibitors for the manufacture of a medicament for the treatment of aids

Publications (1)

Publication Number Publication Date
IL128107A0 true IL128107A0 (en) 1999-11-30

Family

ID=26698971

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12810797A IL128107A0 (en) 1996-08-30 1997-08-28 Pharmaceutical compositions containing a pkc inhibitor

Country Status (15)

Country Link
US (1) US6107327A (cs)
EP (1) EP0830860A1 (cs)
JP (1) JP2002514177A (cs)
KR (1) KR20000035861A (cs)
CN (1) CN1228696A (cs)
AU (1) AU4179497A (cs)
BR (1) BR9711329A (cs)
CA (1) CA2263133A1 (cs)
CZ (1) CZ52099A3 (cs)
EA (1) EA199900245A1 (cs)
HU (1) HUP0002531A2 (cs)
IL (1) IL128107A0 (cs)
NO (1) NO990949L (cs)
PL (1) PL331760A1 (cs)
WO (1) WO1998008509A1 (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291446B1 (en) * 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US20020107193A1 (en) * 2000-11-09 2002-08-08 Glazner Gordon W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators
JP2003327536A (ja) * 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
PH27309A (en) * 1989-11-13 1993-05-28 Merrell Dow Pharma Prevention of glycoprotein enveloped virus infectivity by quinolyl-and isoquinolyloxazone-2-ones
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
WO1995005824A1 (en) * 1993-08-24 1995-03-02 Smithkline Beecham Corporation Aaptamines and method of use thereof
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
DK0657411T3 (da) * 1993-12-07 1999-11-15 Lilly Co Eli Forbedret syntese af bisindolylmaleimider
AU687909B2 (en) * 1993-12-07 1998-03-05 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
WO1998008509A1 (en) 1998-03-05
BR9711329A (pt) 1999-08-17
JP2002514177A (ja) 2002-05-14
HUP0002531A2 (hu) 2001-02-28
KR20000035861A (ko) 2000-06-26
US6107327A (en) 2000-08-22
NO990949D0 (no) 1999-02-26
CA2263133A1 (en) 1998-03-05
AU4179497A (en) 1998-03-19
CN1228696A (zh) 1999-09-15
NO990949L (no) 1999-02-26
EP0830860A1 (en) 1998-03-25
PL331760A1 (en) 1999-08-02
CZ52099A3 (cs) 1999-10-13
EA199900245A1 (ru) 1999-08-26

Similar Documents

Publication Publication Date Title
IL193245A0 (en) Pharmaceutical compositions containing an a?? fragment
ZA977085B (en) Naaladase inhibitors
GB9817698D0 (en) Liquid oral compositions comprising a calcium compound and an acidulan
EP0772592A4 (en) PLA 2 INHIBITORS? WITH 1H-INDOLE FUNCTIONALITY IN POSITION 1
HUP0000180A3 (en) Pharmaceutical compositions comprising flurbiprofen
IL135377A0 (en) Pharmaceutical compositions comprising mtp inhibitors
EG24118A (en) Pharmaceutical compositions
GB9624731D0 (en) Complement inhibitor
HUP0001794A3 (en) Pill dispenser
GB9616672D0 (en) Pharmaceutical compositions
ZA973062B (en) New pharmaceutical formulation of a thrombin inhibitor for parenteral use.
IL112639A0 (en) A pharmaceutical composition containing pravastin
GB9610359D0 (en) Pharmaceutical compositions
ZA9710919B (en) Pharmaceutical compositions containing N-sulphony-lindole derivatives
IL128107A0 (en) Pharmaceutical compositions containing a pkc inhibitor
GB9622681D0 (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
DE69523450D1 (en) Inhibitor
HUP0100349A3 (en) Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor
GB9610136D0 (en) Pharmaceutical compositions
GB9618376D0 (en) Pharmaceutical compositions
GB9725482D0 (en) A notepaper dispenser
GB9607236D0 (en) A dispenser
HUP0003528A3 (en) Pharmaceutical compositions containing dihydropolyprenols
AU2264697A (en) Therapeutic compositions containing a hexahydro-5-pyrimidinamine compound and a morpholine-ether compound